Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SYK vs MDT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MDT Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–3 Matrix Metrics)

MDT Overall Winner 6-Pillar Tally: SYK 3 – 3 MDT Matrix Metrics: SYK 3 – 6 MDT

As of Nov 16, 2026, Medtronic plc (MDT) is the stronger overall head-to-head candidate over Stryker Corporation (SYK) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, R&D & Supply-Chain Moat). SYK carries a Unified Composite Score of 46.5/100 (HOLD) at $310.79 (19.0x Forward P/E, 24.0% operating margin), whereas MDT carries 45.8/100 (HOLD) at $103.38 (17.0x Forward P/E, 20.1% operating margin).

  • Composite vs. Pillar Nuance: While SYK currently prints a higher short-term Unified Composite Score (46.5/100 HOLD vs. MDT 45.8/100 HOLD), MDT captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (20.1% vs. 24.0% operating margin) and revenue trajectory (+13.7% vs. +7.6% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SYK vs MDT
SYK NYSE
Stryker Corporation
Surgical & Medical Instruments & Apparatus
$310.79
+0.37% 1D
Market Cap $118.9B
TTM Revenue $26.3B
Forward P/E 19.0x
Beta / 30D Vol 0.22β · 50% Vol
Unified Composite Score
46.5 / 100 HOLD
Tech 37.0 Fund 49.0 Flow 58.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.5 · SMA20: $312.55 · SMA50: $292.40
MDT NYSE Head-to-Head Winner
Medtronic plc
Electromedical & Electrotherapeutic Apparatus
$103.38
+0.5% 1D
Market Cap $129.2B
TTM Revenue $37.5B
Forward P/E 17.0x
Beta / 30D Vol 0.15β · 33% Vol
Unified Composite Score
45.8 / 100 HOLD
Tech 22.0 Fund 46.0 Flow 69.0 Mom 46.5
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.2% over 20 days), RSI 65
RSI-14: 64.7 · SMA20: $98.99 · SMA50: $93.91

6-Pillar Scorecard Institutional Category Breakdown (SYK 3 – 3 MDT)

Columns: Metric · SYK · MDT
1. Valuation Multiples MDT
Forward P/E 19.0x 17.0x
Trailing P/E 33.3x 24.8x
PEG Ratio 1.54x 1.83x
EV / Revenue 5.0x 4.1x
2. Growth & Scale MDT
Revenue Growth (YoY) +7.6% +13.7%
Earnings Growth (YoY) -11.7% +40.7%
TTM Revenue (USD) $26.3B $37.5B
Market Cap $118.9B $129.2B
3. Profitability & Quality SYK
Gross Margin 65.7% 65.3%
Operating Margin 24.0% 20.1%
Net Profit Margin 13.8% 13.9%
Return on Equity (ROE) 16.0% 10.7%
4. Balance Sheet & Cash Flow SYK
Cash Generation (TTM) $4.57B $6.13B
Cash Flow Margin 17.4% 16.3%
Net Cash / Leverage $11.7B Net Debt (0.64x D/E) $26.5B Net Debt (0.56x D/E)
Dividend Yield 1.10% 2.80%
5. Options & Positioning SYK
Options Structure Phase SURGE CONSOLIDATION
Current IV / %ile 28.1% (5th %ile) 30.6% (12th %ile)
Put/Call OI Skew 0.30x (Call-Skewed) 0.30x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat MDT
OpEx & R&D Intensity 41.7% of Rev ($11.0B) 45.2% of Rev ($17.0B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Concentrated Oligopoly Moat Concentrated Oligopoly Moat
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SYK (3) vs MDT (6)
Institutional Metric SYK MDT Criterion Row Edge
Market Capitalization
Scale
$118.9B $129.2B Larger Scale MDT
Trailing P/E Ratio
Valuation
33.3x 24.8x Lower Multiple MDT
Forward P/E Ratio
Valuation
19.0x 17.0x Lower Multiple MDT
Revenue Growth (YoY)
Growth
+7.6% +13.7% Higher Growth MDT
Operating Margin (TTM)
Profitability
24.0% 20.1% Higher Margin SYK
Net Profit Margin
Profitability
13.8% 13.9% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
16.0% 10.7% Higher ROE SYK
52-Week Range Position
Momentum
36% ($267–$389) 91% ($73–$106) Stronger Trend MDT
Beta / 30D Volatility
Risk Regime
0.22β · 50% Vol 0.15β · 33% Vol Lower Realized Risk MDT
Unified Institutional Score
Composite Signal
46.5 / 100 (HOLD) 45.8 / 100 (HOLD) Higher Composite SYK
Trailing 12M Revenue (USD)
Operating Scale
$26.3B $37.5B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
65.7% 65.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.54x PEG · 5.0x EV/Rev 1.83x PEG · 4.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$4.57B ($11.7B Net Debt (0.64x D/E)) $6.13B ($26.5B Net Debt (0.56x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MDT +3.63 pp
SYK: +5.47% · MDT: +9.1%
3M Horizon MDT +18.47 pp
SYK: -6.21% · MDT: +12.26%
6M Horizon MDT +34.48 pp
SYK: -0.78% · MDT: +33.7%
1Y Horizon MDT +24.3 pp
SYK: -16.77% · MDT: +7.53%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SYK Revenue MDT Revenue SYK Op. Margin MDT Op. Margin Margin Leader
FY2019 $14.9B $30.6B 18.2% 20.5% MDT
FY2020 $14.3B $28.9B 15.5% 16.6% MDT
FY2021 $17.1B $30.1B 15.1% 14.9% SYK
FY2022 $18.4B $31.7B 15.4% 18.2% MDT
FY2023 $20.5B $31.2B 19.0% 17.6% SYK
FY2024 $22.6B $32.4B 16.3% 15.9% SYK
FY2025 $25.1B $33.5B 19.5% 17.8% SYK
FY2026 N/A $36.4B N/A 17.8% MDT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SYK SURGE
8d in phase · OBV DISTRIBUTION
Current IV 28.1%
IV Percentile 5th %ile
Put/Call OI Skew 0.30x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact SYK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MDT CONSOLIDATION
62d in phase · OBV DISTRIBUTION
Current IV 30.6%
IV Percentile 12th %ile
Put/Call OI Skew 0.30x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact MDT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SYK Moat Profile Concentrated Oligopoly Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $118.9B market capitalization and 24.0% operating margin.
OpEx & R&D Reinvestment 41.7% of Rev ($11.0B)
90D Engineering Disclosures 0 Published · Surgical Robotics
MDT Moat Profile Concentrated Oligopoly Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $129.2B market capitalization and 20.1% operating margin.
OpEx & R&D Reinvestment 45.2% of Rev ($17.0B)
90D Engineering Disclosures 0 Published · Surgical Robotics

Investor FAQ SYK vs MDT Key Questions & Quantitative Answers

As of Nov 16, 2026, Medtronic plc (MDT) is the stronger overall head-to-head candidate over Stryker Corporation (SYK) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, R&D & Supply-Chain Moat). SYK carries a Unified Composite Score of 46.5/100 (HOLD) at $310.79 (19.0x Forward P/E, 24.0% operating margin), whereas MDT carries 45.8/100 (HOLD) at $103.38 (17.0x Forward P/E, 20.1% operating margin). Composite vs. Pillar Nuance: While SYK currently prints a higher short-term Unified Composite Score (46.5/100 HOLD vs. MDT 45.8/100 HOLD), MDT captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (20.1% vs. 24.0% operating margin) and revenue trajectory (+13.7% vs. +7.6% YoY).

MDT leads the Growth & Scale pillar: SYK posts +7.6% YoY revenue growth and -11.7% YoY earnings growth on $26.3B TTM revenue (65.7% gross margin, 24.0% operating margin), compared with MDT at +13.7% YoY revenue growth and +40.7% YoY earnings growth on $37.5B TTM revenue (65.3% gross margin, 20.1% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), SYK cumulative revenue shifted +68.8% while MDT shifted +19.0%. In operating R&D and SG&A reinvestment, SYK deploys 41.7% of Rev ($11.0B) (0 90-day corporate R&D disclosures) versus 45.2% of Rev ($17.0B) (0 disclosures) for MDT.

MDT screens cheaper on headline valuation multiples. SYK trades at 19.0x Forward P/E, 33.3x Trailing P/E, 1.54x PEG, and 5.0x EV/Revenue (17.4% FCF margin), whereas MDT trades at 17.0x Forward P/E, 24.8x Trailing P/E, 1.83x PEG, and 4.1x EV/Revenue (16.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SYK (16.0% ROE) versus MDT (10.7% ROE) capital efficiency.

In options market volatility and institutional positioning, SYK carries 28.1% implied volatility (5th %ile, Compressed (<25th %ile)), a 0.30x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.22β · 50% Vol realized risk). By comparison, MDT carries 30.6% implied volatility (12th %ile, Compressed (<25th %ile)), a 0.30x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.15β · 33% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.